Antihypertensive combination drugs containing lisinopril in the treatment of hypertension and concomitant diseases Review article

Main Article Content

Marcin Barylski

Abstract

Combined antihypertensive treatment is increasingly important in patients with high blood pressure, especially with severe hypertension and high cardiovascular risk. Appropriate combinations of antihypertensive drugs have major advantages over monotherapy, such as increased effectiveness and better tolerance, leading to improved long-term compliance. Combined antihypertensive drugs offer additional benefits due to decreased number of tablets and simplified treatment regimen, as well as more rapid blood pressure control. The paper discusses the advantages of such drugs available in the form of combination of lisinopril with amlodipine or hydrochlorothiazide.

Article Details

How to Cite
Barylski , M. (2013). Antihypertensive combination drugs containing lisinopril in the treatment of hypertension and concomitant diseases. Medycyna Faktow (J EBM), 6(2(19), 22-32. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2411
Section
Articles

References

1. Niklas A., Pawlaczyk-Gabriel K., Tykarski A.: Lisinopril. Biblioteka czasopisma Nadciśnienie Tętnicze. Wydawnictwo Medyczne Via Medica, Gdańsk 2010.
2. Gu Q., Burt V.L., Dillon C.F. et al.: Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the national health and nutrition examination survey, 2001 to 2010. Circulation 2012; 126(17): 2105-2114.
3. Indeks leków Medycyny Praktycznej.
4. Inhibitory konwertazy w leczeniu chorób układu sercowo-naczyniowego. Januszewicz A. (red.). Medycyna Praktyczna, Kraków 2005.
5. Pawlaczyk-Gabriel K., Niklas A., Tykarski A.: Zastosowanie terapii skojarzonej lisinoprilem z amlodipiną w leczeniu nadciśnienia tętniczego i jego powikłań. Nadciśnienie Tętnicze 2009; 13(supl. F): 1-12.
6. Malacco E., Santonastaso M., Varì N.A. et al.; Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril Study: Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin. Ther. 2004; 26(6): 855-865.
7. Terpstra W.F., May J.F., Smit A.J. et al.: Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). J. Hypertens. 2004; 22: 1309-1316.
8. Gruppo Italiano per lo Studio Della Sopravvivenza nell Infarcto Miocardico: Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial. J. Am. Coll. Cardiol. 1996; 27: 337-344.
9. Popescu B.A., Macor F., Antonini-Canterin F. et al.; GISSI-3 Echo Substudy Investigators: Left atrium remodeling after acute myocardial infarction (results of the GISSI-3 Echo Substudy). Am. J. Cardiol. 2004; 93(9): 1156-1159.
10. Pizzettib F., Turazzaa F.M., Franzosia M.G. et al.: Cardiovascular medicine incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart 2001; 86: 527-532.
11. Charakterystyka Produktu Leczniczego. Ministerstwo Zdrowia. Departament Polityki Lekowej i Farmacji. Warszawa 2009.
12. Jakubowski P., Drożdż J.: Inhibitory konwertazy angiotensyny w niewydolności serca. Terapia 2011; 3: 24-27.
13. Kazberuk-Tomaszuk A., Małyszko J.: Korzyści ze stosowania lisinoprilu w chorobach układu sercowo-naczyniowego i chorobach nerek. Czego spodziewać się po badaniu HALT-PKD? Medycyna Faktów 2012; 4(17): 14-20.
14. Packer M., Poole-Wilson P.A., Armstrong P.W. et al.: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100(23): 2312-2318.
15. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Heart Journal 2012; 33: 1787-1847.
16. Januszewicz A.: Nadciśnienie tętnicze. Zarys patogenezy, diagnostyki i leczenia. Medycyna Praktyczna, Kraków 2009.
17. Barylski M., Bielecka-Dąbrowa A., Ciebiada M.: Lizinopril w terapii chorób układu sercowo-naczyniowego – skuteczność potwierdzona w badaniach. Geriatria 2011; 5: 55-64.
18. The EUCLID Study Group: Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet 1997; 2: 1787-1792.
19. Chaturvedi N., Sjolie A.K., Stephenson J.M. et al.: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351: 28-31.
20. Crepaldi G., Carta O., Deferrari G. et al.: Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. Diabetes Care 1998; 21: 104-110.
21. Mogensen C.E., Neldam S., Tikkanen I. et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria and non-insulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) study. BMJ 2000; 321: 1440-1444.
22. Potter J.F., Robinson T.G., Ford G.A. et al.: Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo controlled, double blind pilot trial. Lancet Neurol. 2009; 8: 23-24.
23. Hateboer N., van Dijk M., Bogdanova N. et al.: Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 1999; 353(9147): 103-107.
24. Schrier R.: Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 2009; 20: 1888-1893.
25. Chapman A.B., Torres V.E., Perrone R.D. et al.: The HALT polycystic kidney disease trials: design and implementation. Clin. J. Am. Soc. Nephrol. 2010; 5: 102-109.
26. Mancia G., De Backer G., Dominiczak A. et al.: ESH/ESC 2007 Guidelines for the management of arterial hypertension. Rev. Esp. Cardiol. 2007; 60(9): 968, e1-94.
27. Filipiak K.J., Grajek S., Mamcarz A. et al.: Ramipril z amlodipiną – nowy lek złożony w terapii hipotensyjnej. Nadciśnienie Tętnicze 2012; 16(2): 105-119.
28. Tykarski A., Posadzy-Malaczynska A., Wyrzykowski B. et al.: Prevalence of hypertension and effectiveness of its treatment in adult residents of our country. Results of the WOBASZ program. Kardiol. Pol. 2005; 63(6 supl. 4): S614-619.
29. Widecka K., Grodzicki T., Narkiewicz K. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2011. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze 2011; 15(2): 55-82.
30. Sica D.A.: Clinical Management/Principles of Management 1998; 119: 342-344.
31. Mourad J.J., Waeber B., Zannad F. et al.: Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/ indapamide versus a sequential monotherapy or a stepped-care approach. J. Hypertens. 2004; 22(12): 2379-2386.
32. Feldman R.D., Zou G.Y., Vandervoort M.K. et al.: A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009; 53 (4): 646-653.
33. Jamerson K., Weber M.A., Bakris G.L. et al.: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359(23): 2417-2428.
34. Campbell N.R., McAlister F.A., Duong-Hua M. et al.: Polytherapy with two or more antihypertensive drugs to lower blood pressure in elderly Ontarians. Room for improvement. Can. J. Cardiol. 2007; 23(10): 783-787.
35. Wald D.S., Law M., Morris J.K. et al.: Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am. J. Med. 2009; 122(3): 290-300.
36. Yusuf S., Teo K.K., Pogue J. et al.: Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008; 358(15): 1547-1559.
37. Dahlöf B., Sever P.S., Poulter N.R. et al.; ASCOT Investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895-906.
38. Williams B., Lacy P.S., Thom S.M. et al.; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113(9): 1213-1225.
39. Julius S., Kjeldsen S.E., Weber M. et al.; VALUE trial group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363(9426): 2022-2031.
40. Jamerson K., Weber M.A., Bakris G.L. et al.; ACCOMPLISH Trial Investigators: Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. N. Engl. J. Med. 2008; 359: 2417-2428.
41. Barylski M.: Skuteczność amlodipiny w terapii nadciśnienia tętniczego – dowody mówią same za siebie. Choroby Serca i Naczyń 2012; 9(2): 68-84.
42. Farsang C.; HAMLET Trial Investigation: Advantages of lisinopril amlodipin fix combination therapy in hypertension. A comparative study of the efficacy and tolerability of amlodipin 5 mg and lisinopril 10 mg administrated separately and in combination in hypertension. Hypertonia es Nephrologia 2004; 8: 72-78.
43. Farsang C., Abraham G., Kovacs P. et al.: The effictivity and safety of Amlodipin-Lisinopril Fix-combination in patients with ESSential hypertension (ALFESS Study). Hypertonia es Nephrologia 2009; 13: 81-87.
44. Bissinger A., Barylski M.: Terapia skojarzona w leczeniu nadciśnienia tętniczego. Wytyczne PTNT 2011 oraz ESH/ESC. Lekarz Rodzinny 2011; 11(171): 1034-1045.
45. Buter H., Hemmelder M.H., Navis G. et al.: The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol. Dial. Transplant. 1998; 13: 1682-1685.
46. Pool J.L., Gennari J., Goldstein R. et al.: Controlled multicenter study of the antihypertensive effects of lisinopril, hydrochlorothiazide, and lisinopril plus hydrochlorothiazide in the treatment of 394 patients with mild to moderate essential hypertension. J. Cardiovasc. Pharmacol. 1987; 9(supl. 3): S36-S42.
47. Chrysant S.G.: Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination. A large multicenter study. Lisinopril-Hydrochlorothiazide Group. Arch. Intern. Med. 1994; 154: 737.
48. Mancia G., Grassi G.: Antihypertensive effects of combined lisinopril and hydrochlorothiazide in elderly patients with systodiastolic or systolic hypertension: results of a multicenter trial. J. Cardiovasc. Pharmacol. 1997; 30: 548-553.
49. Reaven G.M., Clinkingbeard C., Jeppesen J. et al.: Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am. J. Hypertens. 1995; 8: 461-466.
50. Poldermans D., Glazes R., Kargiannis S. et al.: Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin. Ther. 2007; 29: 279-289.
51. Fogari R., Mugellini A., Zoppi A. et al.: Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J. Hum. Hypertens. 2006; 20: 177-185.
52. Mc Innes G.T., O’Kane K.P., Istad H. et al.: Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. J. Hum. Hypertens. 2000; 14: 263-269.

Most read articles by the same author(s)

1 2 3 > >>